MSMatthew Jonathon Stotts

Matthew Jonathon Stotts

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew Jonathon Stotts has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The age 70 threshold: Evidence of left-digit bias in liver transplantation

    by Mohamed A. Omar, Marcel Katrib, Nathan Tofteland, William J. Salyers, Hunter B. Moore, Matthew J. Stotts

    Was not provided for this article.

  • Open Access

    Brucellosis. A Rare Cause of Biliary Dysplasia and Ampullary Adenocarcinoma?

    by Zachary Vinton, Kevin Wolfe, Sean MacBride, Thomas Heffron, Vimal Jhaveri, Andrea K. Sotelo, Mark Rosenblatt, Clark Kulig, Matthew Stotts

    Brucellosis, a zoonotic bacterial infection often characterized by nonspecific symptoms including fever, night sweats, and weight loss, has a prolonged and recurrent course, often leading to chronic symptoms if inadequately treated. Hepatic involvement is well-documented with manifestations ranging from mild hepatitis to hepatic abscesses and granulomas. However, the association of brucellosis with biliary dysplasia or ampullary adenocarcinoma has not been previously reported in medical literature. We present a 68-year-old man with hepatic granulomatosis due to chronic brucellosis complicated by numerous episodes of ascending cholangitis secondary to choledocholithiasis and common bile duct strictures, with high-grade dysplasia and development of ampullary adenocarcinoma.

  • Reproductive health and liver disease: a patient-friendly summary of the 2021 AASLD guidance

    by Cynthia Levy, Carla W. Brady, Norah Terrault, Matthew J. Stotts, Monika Sarkar

    Watch the interview with the author.


  • Open Access

    Survival outcomes in adult recipients using pediatric deceased donor liver grafts. A PSM analysis from the OPTN/UNOS liver transplant registry

    by Paola A. Vargas, Mohamad El Moheb, Zachary Henry, Nicolas Intagliata, Feng Su, Matthew Sttots, Curtis Argo, Shawn Pelletier, Jose Oberholzer, Nicolas Goldaracena


  • Red blood transfusion as a potential source for false‐positive phosphatidylethanol levels

    by Matthew J. Stotts, Michael G. Risbano, James D. Gorham, Angelo D'Alessandro


  • Open Access

    Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites

    by Matthew J. Stotts, Amanda Cheung, Muhammad B. Hammami, David J Westrich, Eric Anderson, Lauren Counts, Alex S. Befeler, Adrian M. Di Bisceglie, Charlene Prather

    Background Bacterial translocation plays a pivotal role in the natural course of cirrhosis and its complications. Serum-derived bovine immunoglobulin (SBI) is an oral medical food that has been shown to both reduce inflammation in the intestines and neutralize bacteria. It represents a unique intervention that has not been studied in this population. Methodology We conducted a prospective open-label trial with an eight-week treatment phase of SBI. Individuals were assessed using lactulose breath testing, serum markers for enterocyte damage and bacterial translocation, and the Chronic Liver Disease Questionnaire (CLDQ) prior to and after completion of the treatment phase. Results We evaluated nine patients with a diagnosis of decompensated cirrhosis with asci Les. Subjects had a mean Model for End-Stage Liver Disease (MELD) score of 11.6 +/- 3.0 and were not taking lactulose or antibiotics. All subjects tolerated SBI well with no significant adverse events or changes to any of the six domains of the CLDQ. Laboratory tests including liver tests and MELD score remained stable over the course of treatment. There were no significant changes in the rates of small intestinal bacterial overgrowth (55.6% vs 55.6%, p =1.00) or serum levels of lipopolysaccharide-binding protein, intestinal fatty acid-binding protein, or soluble CD14 (p-values 0.883, 0.765, and 0.748, respectively) when comparing values prior to and immediately after treatment. Conclusions No adverse events or significant changes to the quality of life were detected while on treatment. There were no statistically significant differences in our outcomes when comparing individuals before and after treatment in this small prospective proof-of-concept pilot study. Further prospective randomized studies could be beneficial.


  • The Spectrum of Disease Severity in Cirrhosis and Its Implications for Hemostasis

    by Matthew J. Stotts, Ton Lisman, Nicolas M. Intagliata

    Bleeding and thrombosis are both common complications that patients with advanced liver disease experience. While hemostatic pathways remain largely intact with cirrhosis, this balance can quickly shift in the direction of bleeding or clotting in an unpredictable manner. A growing body of literature is attempting to shed light on difficult scenarios that clinicians often face, ranging from predicting and mitigating bleeding risk in those who need invasive procedures to determining the best strategies to manage both bleeding and thrombotic complications when they occur. Studies examining hemostasis in those with advanced liver disease, however, often include heterogeneous cohorts with varied methodology. While these studies often select a cohort of all types and degrees of cirrhosis, emerging evidence suggests significant differences in underlying systemic inflammation and hemostatic abnormalities among specific phenotypes of liver disease, ranging from compensated cirrhosis to decompensated cirrhosis and acute-on-chronic liver failure. It is paramount that future studies account for these differing disease severities if we hope to address the many critical knowledge gaps in this field.


  • The Changing Burden of Alcoholic Hepatitis: Rising Incidence and Associations with Age, Gender, Race, and Geography

    by Sahil D. Doshi, Matthew J. Stotts, Rebecca A. Hubbard, David S. Goldberg

    Alcoholic hepatitis is a major cause of morbidity and mortality. However, there are limited population-based data on its incidence, demographics, and temporal trends. We performed a retrospective cohort study using the State Inpatient Databases from Florida, Massachusetts, New York, and Washington from 2010 to 2014. We included patients aged 20–79 years admitted with alcoholic hepatitis and calculated incidence using population denominators obtained from the Centers for Disease Control and Prevention WONDER database. We fit multivariable Poisson regression models to explore interactions between alcoholic hepatitis incidence rates and several predictors including state, calendar year, age, race/ethnicity, and gender. Among 56,973 unique individuals with alcoholic hepatitis, the majority were male (39,702; 69.7%) and white non-Hispanic (40,934; 72.0%). In multivariable Poisson models, there was a significant interaction between calendar year and age group (p < 0.001), with the highest incidence rates in those ages 40–49 and 50–59 across all years. The absolute increase in incidence rate across calendar years was highest in the 20–29 and 30–39 age groups in every state. Female gender was associated with a lower rate (incidence rate ratio (IRR) 0.42, 95% confidence interval (CI) 0.41–0.42, p < 0.001). Compared to white non-Hispanics, black non-Hispanics (IRR 0.79, CI 0.77–0.81, p < 0.001) and Hispanics (0.66, CI 0.65–0.68, p < 0.001) had lower incidence rates. The incidence of alcoholic hepatitis in the USA varies by age, gender, race/ethnicity, and state of residence. The group with the fastest rising incidence is those aged 20–39. More work is needed to evaluate the reasons for the temporal trends for admissions for alcoholic hepatitis.


  • Coagulation testing and management in liver disease patients

    by Matthew J. Stotts, Jessica P.E. Davis, Neeral L. Shah

    Purpose of review: The present article aims to provide clinicians with an overview of coagulation testing in individuals with liver disease, to discuss available procoagulants and the rationale for their use, and to provide management strategies in a variety of common clinical scenarios. Recent findings: Clinicians and researchers are gaining an increased understanding of the shortfalls of assessing bleeding risk using traditional tests of coagulation. The use of global tests of clot formation, including viscoelastic testing and thrombin generation analysis, continues to evolve and guide the management of these patients. Summary: Abnormal coagulation testing in individuals with cirrhosis leads to a variety of difficult clinical scenarios that can be challenging for practitioners. With advanced liver disease, changes in the traditional tests of hemostasis such as the international normalized ratio reflect decreased synthesis of procoagulant factors but do not capture concomitant decreases in anticoagulant factors. In this setting, transfusion thresholds targeting platelet and fibrinogen goals may provide an effective strategy to optimize clot formation. Global tests of clot formation provide practical information to clinicians and can help guide decision making, although optimal target levels have not been validated.